|
1.
|
|
5 p, 332.1 KB |
Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
/
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Giuliani, Rosa (San Camillo Forlanini Hospital) ;
Arnold, Dirk (CUF Hospitals) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Casali, Paolo Giovanni (Fondazione IRCCS National Cancer Institute) ;
Cervantes, Andrés (Clinic Hospital) ;
Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Jassem, Jacek (Medical University of Gdansk) ;
Pentheroudakis, George (University of Ioannina) ;
Peters, Solange (Centre Hospitalier Universitaire Vaudois) ;
Rauh, Stefan (Hospital Center Emile Mayrisch) ;
Zielinski, Christoph C. (Medical University of Vienna) ;
Stahel, Rolf A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Voest, Emile (University Hospital Zurich (Suïssa)) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Ciardiello, Fortunato (Second University of Naples) ;
Universitat Autònoma de Barcelona
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. [...]
2017 -  10.1136/esmoopen-2016-000142
ESMO open, Vol. 1 (january 2017)
|
|
|
2.
|
|
5 p, 637.4 KB |
Educational needs in gastrointestinal cancer : a consensus position paper from the ESMO Gastrointestinal Cancer Faculty
/
Lordick, Florian (Leipzig University Medical Center) ;
Obermannova, Radka (Masaryk University) ;
Vola, Doris (European Society for Medical Oncology) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
Mcgregor, Keith (European Society for Medical Oncology) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Ciardiello, Fortunato (Second University of Naples) ;
Cervantes, Andrés (Universitat de València)
Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. [...]
2019 - 10.1136/esmoopen-2019-000533
ESMO open, Vol. 4 (july 2019)
|
|
|
3.
|
|
|
4.
|
|
1 p, 46.9 KB |
Carta d'Andrés Cervantes, José López, José Flores, Martín Moreno, Manuel González, Antonio Flores y Lorenzo González a Rafael Lorente
/
Cervantes, Andrés ;
Lorente, Rafael
Petició, per part d'alguns veïns de Palomares, a Rafael Lorente, advocat i testimoni presencial de l'accident nuclear de Palomares, de que col·labori amb els advocats que porten el cas.
1966
|
|
|
5.
|
|
9 p, 1023.2 KB |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial
/
Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ;
Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Cervantes, Andrés (Universitat de València) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gil Calle, S. (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Mizuguchi, Hirokazu (Taiho Oncology) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235
|
|
|
6.
|
|
6 p, 1.4 MB |
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Lampis, Andrea (The Institute of Cancer Research. Department of Molecular Pathology) ;
Hahne, Jens Claus (The Institute of Cancer Research. Department of Molecular Pathology) ;
Ghidini, Michele (The Institute of Cancer Research. Department of Molecular Pathology) ;
Lote, Hazel (The Institute of Cancer Research. Department of Molecular Pathology) ;
Zito, Domenico (The Institute of Cancer Research. Department of Molecular Pathology) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Glimelius, Bengt (University of Uppsala. Genetics and Pathology, Experimental and Clinical Oncology. Department of Immunology) ;
Cervantes, Andrés (University of Valencia. Biomedical Research Institute INCLIVA. Department of Haematology and Medical Oncology) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Wilson, Sanna Hulkki (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Peckitt, Clare (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Tait, Diana (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Oates, Jacqueline (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Braconi, Chiara (The Institute of Cancer Research. Department of Cancer Therapeutics) ;
Valeri, Nicola (The Institute of Cancer Research. Department of Molecular Pathology) ;
Universitat Autònoma de Barcelona
Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab. [...]
2016 - 10.1093/carcin/bgw073
Carcinogenesis, Vol. 37 (july 2016) , p. 852-857
|
|
|
7.
|
|
9 p, 306.4 KB |
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Hendlisz, A. (Institut Jules Bordet (Belgium)) ;
Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ;
Sastre Valera, Javier (Hospital Clínico San Carlos (Madrid)) ;
Cervantes, Andrés (Instituto de Investigación Sanitaria INCLIVA (València, Comunitat Valenciana)) ;
Varea, R. (Eli Lilly and Company (Spain)) ;
Chao, G. (Eli Lilly and Company (USA)) ;
Wallin, J. (Eli Lilly and Company (Suècia)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380
|
|
|
8.
|
|
6 p, 225.1 KB |
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Lampis, Andrea (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Hahne, Jens Claus (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Braconi, Chiara (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ;
Cervantes, Andrés (Universitat de València. Departament d'Hematologia i Oncologia Mèdica) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
González De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Valeri, Nicola (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941
|
|
|
9.
|
|
8 p, 207.5 KB |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer
/
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Cervantes, Andrés (Universitat de València. Biomedical Research Institute) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Roselló, Susana (Universitat de València. Biomedical Research Institute) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Laffranchi, B. (Merck Serono SA) ;
Jego, V (Merck Serono SA) ;
von Richter, O. (Merck KGaA) ;
Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
